Abstract
30 patients with TS. aged 4.6-12.6 years were randomly allocated to receive oral ethinyl oestradiol (EE2) (0.5-2.0ug/day) or oxandrolone (OX) (0.625-1.25mg/day). Groups were matched for age, karyotype, pre-treatment height SDS for TS and height velocity SDS for TS (HV SDS) (Ranke).HV SDS results (SD) after 0.5-1.0 yrs were as follows:Response to EE2 was slightly less consistent than to OX (p < 0.05), with 2 non-responders.Both treatments were well tolerated. Cliteromegaly was noted in 2 on OX; 3 on EE2 had early breast development.24 hr growth hormone (GH) profiles were performed in 10 of each group before and during treatment. The sum of GH pulse amplitudes (SPA) was calculated using a computer algorithm (PULSAR). GH SPA was not changed by either treatment.Used in appropriate dosage, both agents are safe, simple and effective agents in Turner syndrome. Neither appears to work via increased CH secretion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
